A Nuclear Medicine targeting the type of cancer that killed Steve Jobs won a green light from EU regulators on Friday, boosting prospects for its developer Advanced Accelerator Applications. The European Medicines Agency said its Committee for Medicinal Products for Human Use (CHMP) had recommended the product, Lutathera, setting the stage for full approval within a couple of months.Chief Executive Stefano Buono told Reuters the company was also ready to re-file its application for U.S.
marketing approval with the Food and Drug Administration this month. Lutathera is unusual in harnessing the same molecule that is already used to diagnose cancer to also deliver treatment.The radiopharmaceutical works by hitting cancer cells with high energy electrons, just like radiotherapy, but the injection targets gastroenteropancreatic neuroendocrine tumours (NETs) that over-express a certain…
